You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

 

Online download statistics by month:

Online download statistics by month: July 2021 to March 2026

AbstractFullPdf
Jul 2021464468135
Aug 2021287288137
Sep 202121621688
Oct 202122122268
Nov 202115415567
Dec 202111311333
Jan 202214615468
Feb 2022879140
Mar 2022828553
Apr 202210511337
May 202216016345
Jun 202213213832
Jul 202212913332
Aug 202213513549
Sep 202210411038
Oct 202212312852
Nov 2022747540
Dec 2022737323
Jan 202310610633
Feb 2023979924
Mar 2023767731
Apr 2023556420
May 2023979821
Jun 2023868618
Jul 2023777735
Aug 2023868626
Sep 2023484921
Oct 2023404021
Nov 2023515215
Dec 2023464621
Jan 2024363728
Feb 2024595929
Mar 2024979885
Apr 202411611736
May 2024727226
Jun 2024676827
Jul 202411411520
Aug 2024797824
Sep 2024909232
Oct 202410711034
Nov 2024828322
Dec 202411911926
Jan 2025858535
Feb 202512812845
Mar 202511411442
Apr 202514114252
May 202511411727
Jun 202510610837
Jul 2025110
Mar 2026110
Total539854841950